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PES15 A COMPARISON OF QUALITY OF LIFE IN PATIENTS WITH AGE-RELATED MACULAR DEGENERATION (AMD) WITH MONOCULAR VERSUS BILATERAL DISEASE
Pfizer Global Pharmaceuticals, Pfizer, Inc, New York, NY, USA; 2 Queen's University, Kingston, ON, Canada OBJECTIVES: To determine if the quality-of-life of AMD patients with monocular visual dysfunction differs from that of those with bilateral visual dysfunction. METHODS: A crosssectional study (n = 168) determined if there was a statistically significant difference in patient-reported health related qualityof-life (HRQoL) of AMD patients with monocular versus bilateral visual dysfunction. Subjects underwent a series of interviewer-administered techniques to ascertain their HRQoL, including the Visual Function Index (VF-14) and patient preferences elicited through both the time tradeoff (TTO) and standard reference gamble (SRG). Visual acuity obtained from a subject's better-and worse-seeing eye was categorized as 20/20 to 20/40, 20/40-20/70, 20/80-20/200 , and worse than 20/200. Based on the various combinations of these 4 visual acuity groupings in the better-seeing (BSE) and worse-seeing eyes (WSE), subjects were classified into one of 10 subgroups. Multivariate linear regression determined if an association existed between various clinical variables and HRQoL. RESULTS: The mean age was 72 years; 63% were females. Mean scores were: VF-14, 66.1; TTO, 0.86; SRG, 0.89. Subjects with binocular visual dysfunction reported a lower HRQoL compared to those with monocular dysfunction (p < 0.001); mean differences in the TTO, SRG, and VF-14 were 0.19 (SE = 0.04), 0.14 (SE = 0.04), and 59.2 (SE = 3.9), respectively. Multivariate models demonstrated that only visual acuity subgrouping, a function of acuity in both the BSE and WSE, was associated with HRQoL score (overall eta 2 = 34.8%, p < 0.01, and partial eta 2 equal to 22% [TTO], 20% [SRG] and 60% ). Models including both BSE and WSE visual acuity explained an additional 10% in HRQoL variability compared to models with only BSE visual acuity. CONCLUSIONS: Subjects with binocular visual dysfunction reported a significantly lower HRQoL as compared to those with monocular dysfunction. These results suggest that binocular vision is a better predictor of HRQoL in AMD than only visual acuity in the BSE. The lack of specific ICD-9 codes and under selfreporting and diagnosis of ChHD suggests a need for a selfassessment survey to identify ChHD. This pilot study was conducted to validate a newly designed self-assessment questionnaire and the Skindex-29 QoL instrument for use by ChHD patients. METHODS: A clinical questionnaire, consisting of 16 questions, was developed to identify patients with ChHD and to assess its severity, through patient self-administration. Sensitivity, specificity, and receiver operating characteristic (ROC) curve were used to evaluate how closely the ChHD diagnosis based on self-assessment concurred with physician's diagnoses. Also, Skindex-29, a QoL instrument with 29 questions not previously validated in a ChHD population, was evaluated for internal consistency and construct validity for ChHD patients in this study. Forty-patients (ChHD n = 20; other skin disorders n = 20), with a mean age of 46.6 ± 14.8 years and 30% males, were randomly selected from a dermatology clinic in Louisville, Kentucky for this pilot study. RESULTS: The performance of the clinical questionnaire matched the physicians' diagnosis in identifying ChHD with a sensitivity of 85%, a specificity of 95%, and an area under the ROC curve of 0.83. The internal consistency of the Skindex-29 was higher than that reported previously in a general dermatology population, with a Cronbach alpha of 0.77 to 0.94 for 3 different (symptoms, emotions and functioning) domains. The construct validity of Skindex-29 was evaluated by examining the correlation between the overall score and physician's assessment of ChHD severity. The Pearson rho was 0.55 (p = 0.07), slightly lower than that reported previously, but higher than that reported for other QoL instruments. CONCLUSIONS: This study indicates that the newly developed ChHD self-assessment instrument and the Skindex-29 questionnaire appear to have reasonable performance and validity for ChHD patients. Further validation studies with a larger sample size will be needed to confirm these findings.
PES16 VALIDATION OF A NEW SELF-ASSESSMENT QUESTIONNAIRE AND THE SKINDEX-29 QUALITY OF LIFE (QOL) INSTRUMENT FOR CHRONIC HAND DERMATITIS (CHHD): A PILOT STUDY
PES17 IMPROVED HEALTH-RELATED QUALITY OF LIFE FOLLOWING SUSTAINED REDUCTIONS IN ANTI DS-DNA ANTIBODYS [ÁDSDNA AB] IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) AFTER TREATMENT WITH LJP394
Crawford B / 3 of all ÁdsDNA Ab determinations defined "responders". Minimal clinically important differences [MCID] were based on a 15-point global change scale. RESULTS: In phase 3, 31.4% patients were responders, 63 in LJP394, 28 in placebo; a ratio of 2.25 favoring active treatment. At 6 months, 31.3% were responders: 59 LJP394 and 27 placebo; a ratio of 2.2. At 6 months, responders reported improvement in all domains of SF-36 with the largest increases in bodily pain (8.2), vitality (8.0), general health perceptions (6.6) and physical function (5.7). Non-responders reported worsening in all but 3 domains, which remained unchanged (vitality (1.3), mental health (0.9), and role emotional (0.0)). At 12 months, 43 LJP394 and 24 placebo treated patients were responders; a ratio of 1.8; 35.3% overall. Improvements reported by responders increased by month 12, with largest changes in role physical (13.8), vitality (10.2), general health profile (9.3), and bodily pain (7.3), again with no change or deterioration in nonresponders. Improvements in domain scores were reflected in physical component summary [PCS] score. MCID was determined to range from 6.7 to 11.4 points in domain and 3.4 to 3.9 in PCS scores, consistent with literature reported estimates of 5-10 and 2.5-5.0 points. CONCLUSION: Sustained reductions in ÁdsDNA Ab levels lead to improvement in patient reported HRQOL. These improvements are clinically meaningful, regardless of treatment group. LJP394 administration resulted in 1.8 to 4.0 times more responders than placebo. PES18  THE IMPACT OF THE SYSTEM TO MANAGE ACCUTANE-RELATED TERATOGENICITY  TM (SMART  TM ) RISK   MANAGEMENT PROGRAM ON ISOTRETINOIN  PRESCRIBING TRENDS 
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